idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
idw - Informationsdienst
Wissenschaft
When the liver is damaged by chronic diseases, it has the ability to regenerate itself. Cancer, however, can develop during the regeneration process. A team of researchers led by Ludovic Vallier, Einstein Professor for Stem Cells in Regenerative Therapies at the Berlin Institute of Health at Charité (BIH), recently showed that liver regeneration and tumor development might share common underlying mechanisms. The European Research Council (ERC) has now awarded an ERC Advanced Grant, worth €2.5 million over five years, to Vallier.
He aims to use the grant to further advance the understanding of the mechanisms behind liver regeneration and tumor development, leveraging this knowledge to devise novel therapies tailored to patients’ individual needs.
Ludovic Vallier grows mini-livers, so-called organoids, to study how liver diseases develop and how they can be treated and prevented. A key part of this, according to Vallier, Einstein Professor for Stem Cells in Regenerative Therapies at the Berlin Institute of Health at Charité (BIH) and Max Planck Fellow at the Max Planck Institute for Molecular Genetics (MPIMG), involves deciphering the mechanisms of liver regeneration. These enable the repair of damaged cells, but can also lead to tumor development in the case of chronic liver diseases should something go wrong during the cell repair process. As part of a project called FunChol, Vallier seeks to shed light on these mechanisms while using a translational medicine approach to develop novel therapeutic strategies. The European Research Council (ERC) has awarded him an ERC Advanced Grant, which provides €2.5 million to support this research over a five-year period.
Changing how chronic diseases are understood and treated
While current treatments for liver disease focus on limiting tissue injury, Vallier and his team want to go deeper and look for new therapeutic methods. Using the findings from the FunChol project, they aim to produce cells that are not only resistant to liver disease, but also promote tissue regeneration while preventing cancer development, which normally occurs in the context of advanced liver diseases like metabolic disorders. The identification of biomarkers for the diagnosis and prognosis of the diseases should also pave the way for personalized treatments for patients. These biomarkers are characteristics found in blood or tissue that indicate various processes of liver regeneration in the patient’s body, which could help physicians choose the most suitable form of therapy for each individual patient.
In the funded project, the scientists will combine state-of-the-art methods from the fields of single-cell analysis, bioengineering, and human in vitro organoid systems. They anticipate that the project will bring about a significant change in the fundamental understanding of chronic diseases.
Enthusiasm can make all the difference
“It’s a privilege to be receiving my third ERC grant,” says Vallier. “A grant like this is unique as it gives us a lot of freedom in our research pursuits. We can develop new lines of inquiry and follow solely our scientific curiosity and enthusiasm. For me, this is still the best way to develop impactful research and translational applications that ultimately help patients.”
About Ludovic Vallier
Further information about Ludovic Vallier’s work can be found here:
https://www.bihealth.org/en/notices/regenerative-hepatology
A press release about the Nature paper (Gribben et al., Nature 2024) on liver regeneration mechanisms can be found here:
https://www.bihealth.org/en/notices/researchers-of-the-bih-decipher-mechanisms-o...
Contact
Konstanze Pflüger
Head of Communications and Press Officer
Berlin Institute of Health at Charité (BIH)
+49 (0) 30 450 543019
Konstanze.pflueger@bih-charite.de
www.bihealth.org
---------------------------
About the Berlin Institute of Health at Charité (BIH)
The mission of the Berlin Institute of Health at Charité (BIH) is medical translation: transferring biomedical research findings into novel approaches to personalized prediction, prevention, diagnostics and therapies and, conversely, using clinical observations to develop new research ideas. The aim is to deliver relevant medical benefits to patients and the population at large. As the translational research unit within Charité, the BIH is also committed to establishing a comprehensive translational ecosystem – one that places emphasis on a system-wide understanding of health and disease and that promotes change in the biomedical translational research culture. The BIH was founded in 2013 and is funded 90 percent by the Federal Ministry of Education and Research (BMBF) and 10 percent by the State of Berlin. The founding institutions, Charité – Universitätsmedizin Berlin and Max Delbrück Center, were independent member entities within the BIH until 2020. Since 2021 the BIH has been integrated into Charité as its so-called third pillar. The Max Delbrück Center is now the Privileged Partner of the BIH.
https://www.bihealth.org/en/notices/developing-new-therapeutic-strategies-for-li...
Merkmale dieser Pressemitteilung:
Journalisten, Wissenschaftler
Ernährung / Gesundheit / Pflege, Medizin
überregional
Forschungsprojekte, Wettbewerbe / Auszeichnungen
Englisch
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).
